FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591866999> ?p ?o ?g. }

• W2591866999 endingPage "32682" @default.
• W2591866999 startingPage "32668" @default.
• W2591866999 abstract "// Dominik Thomas Koch 1 , Anja Pickhard 1 , Lena Gebel 1 , Anna Maria S. Buchberger 1 , Murat Bas 1 , Carolin Mogler 2 , Rudolf Reiter 3 , Guido Piontek 1 , Markus Wirth 1 1 Department of Otorhinolaryngology Head and Neck Surgery, Technical University of Munich, 81675 Munich, Germany 2 Institute of Pathology, Technical University of Munich, 81675 Munich, Germany 3 Department of Otolaryngology Head and Neck Surgery, Section of Phoniatrics and Pedaudiology, University of Ulm, 89070 Ulm, Germany Correspondence to: Markus Wirth, email: markus.wirth@tum.de Keywords: head and neck squamous cell cancer, EGFR variant III, cetuximab, TKI, radiation Received: October 11, 2016      Accepted: February 21, 2017      Published: March 06, 2017 ABSTRACT Background: The epidermal growth factor receptor (EGFR) is an important regulator of cell growth and survival, and is highly variable in tumor cells. The most prevalent variation of the EGFR extracellular domain is the EGFR variant III (EGFRvIII). Some studies imply that EGFRvIII may be responsible for the poor response to the monoclonal EGFR-antibody Cetuximab, used therapeutically in head and neck squamous cell carcinoma (HNSCC). Due to inconsistent data in the literature regarding EGFRvIII prevalence and clinical relevance in HNSCC, especially its predictive value, we examined EGFRvIII-transfected cell lines and patient tissue samples. Results: In contrast to other recent publications, we were able to demonstrate EGFRvIII expression in HNSCC. However, we noted that the different detection methods yielded inconsistent results. Furthermore, our EGFRvIII transfected and EGFR wild type cell lines exhibited similar characteristics and response rates in the performed in vitro experiments. Materials and Methods: We conducted various inhibition and combined irradiation experiments using three EGFRvIII-transfected cell lines. Moreover, a patient cohort of 149 cases consisting of formalin fixed and paraffin embedded (FFPE) and fresh-frozen specimens was assayed via reverse transcriptase PCR (rtPCR) with gel electrophoresis and sequencing for EGFRvIII prevalence. In the rtPCR assays, we used five previously published EGFRvIII primers and EGFRvIII-positive glioblastoma tissue as a positive control. In addition, immunohistochemical staining was conducted. Conclusions: EGFRvIII can be detected in HNSCC patient samples. Nevertheless, the low prevalence and similar response rates to targeted drugs and irradiation in vitro cast doubt regarding the clinical relevance of EGFRvIII in HNSCC." @default.
• W2591866999 created "2017-03-16" @default.
• W2591866999 creator A5017656696 @default.
• W2591866999 creator A5023042888 @default.
• W2591866999 creator A5023140594 @default.
• W2591866999 creator A5035475099 @default.
• W2591866999 creator A5041541940 @default.
• W2591866999 creator A5044898027 @default.
• W2591866999 creator A5060123933 @default.
• W2591866999 creator A5073088871 @default.
• W2591866999 creator A5073189385 @default.
• W2591866999 date "2017-03-06" @default.
• W2591866999 modified "2023-09-27" @default.
• W2591866999 title "Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation" @default.
• W2591866999 cites W1486118213 @default.
• W2591866999 cites W1599518523 @default.
• W2591866999 cites W1976504918 @default.
• W2591866999 cites W1981219430 @default.
• W2591866999 cites W1986026085 @default.
• W2591866999 cites W1988106671 @default.
• W2591866999 cites W1988635309 @default.
• W2591866999 cites W2024441247 @default.
• W2591866999 cites W2025029856 @default.
• W2591866999 cites W2082969979 @default.
• W2591866999 cites W2092692114 @default.
• W2591866999 cites W2094796180 @default.
• W2591866999 cites W2097152766 @default.
• W2591866999 cites W2118458295 @default.
• W2591866999 cites W2125680248 @default.
• W2591866999 cites W2127591631 @default.
• W2591866999 cites W2139473501 @default.
• W2591866999 cites W2139819066 @default.
• W2591866999 cites W2140407529 @default.
• W2591866999 cites W2152458015 @default.
• W2591866999 cites W2159506146 @default.
• W2591866999 cites W2161001139 @default.
• W2591866999 cites W2161764128 @default.
• W2591866999 cites W2232770029 @default.
• W2591866999 cites W2341228894 @default.
• W2591866999 cites W2343460159 @default.
• W2591866999 cites W2917837889 @default.
• W2591866999 cites W1903839759 @default.
• W2591866999 doi "https://doi.org/10.18632/oncotarget.15949" @default.
• W2591866999 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5464818" @default.
• W2591866999 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28427242" @default.
• W2591866999 hasPublicationYear "2017" @default.
• W2591866999 type Work @default.
• W2591866999 sameAs 2591866999 @default.
• W2591866999 citedByCount "4" @default.
• W2591866999 countsByYear W25918669992018 @default.
• W2591866999 countsByYear W25918669992019 @default.
• W2591866999 countsByYear W25918669992022 @default.
• W2591866999 countsByYear W25918669992023 @default.
• W2591866999 crossrefType "journal-article" @default.
• W2591866999 hasAuthorship W2591866999A5017656696 @default.
• W2591866999 hasAuthorship W2591866999A5023042888 @default.
• W2591866999 hasAuthorship W2591866999A5023140594 @default.
• W2591866999 hasAuthorship W2591866999A5035475099 @default.
• W2591866999 hasAuthorship W2591866999A5041541940 @default.
• W2591866999 hasAuthorship W2591866999A5044898027 @default.
• W2591866999 hasAuthorship W2591866999A5060123933 @default.
• W2591866999 hasAuthorship W2591866999A5073088871 @default.
• W2591866999 hasAuthorship W2591866999A5073189385 @default.
• W2591866999 hasBestOaLocation W25918669991 @default.
• W2591866999 hasConcept C108516343 @default.
• W2591866999 hasConcept C121608353 @default.
• W2591866999 hasConcept C126322002 @default.
• W2591866999 hasConcept C141071460 @default.
• W2591866999 hasConcept C142724271 @default.
• W2591866999 hasConcept C143998085 @default.
• W2591866999 hasConcept C159654299 @default.
• W2591866999 hasConcept C203014093 @default.
• W2591866999 hasConcept C2776530083 @default.
• W2591866999 hasConcept C2776833033 @default.
• W2591866999 hasConcept C2779438470 @default.
• W2591866999 hasConcept C2779998722 @default.
• W2591866999 hasConcept C502942594 @default.
• W2591866999 hasConcept C509974204 @default.
• W2591866999 hasConcept C542903549 @default.
• W2591866999 hasConcept C71924100 @default.
• W2591866999 hasConceptScore W2591866999C108516343 @default.
• W2591866999 hasConceptScore W2591866999C121608353 @default.
• W2591866999 hasConceptScore W2591866999C126322002 @default.
• W2591866999 hasConceptScore W2591866999C141071460 @default.
• W2591866999 hasConceptScore W2591866999C142724271 @default.
• W2591866999 hasConceptScore W2591866999C143998085 @default.
• W2591866999 hasConceptScore W2591866999C159654299 @default.
• W2591866999 hasConceptScore W2591866999C203014093 @default.
• W2591866999 hasConceptScore W2591866999C2776530083 @default.
• W2591866999 hasConceptScore W2591866999C2776833033 @default.
• W2591866999 hasConceptScore W2591866999C2779438470 @default.
• W2591866999 hasConceptScore W2591866999C2779998722 @default.
• W2591866999 hasConceptScore W2591866999C502942594 @default.
• W2591866999 hasConceptScore W2591866999C509974204 @default.
• W2591866999 hasConceptScore W2591866999C542903549 @default.
• W2591866999 hasConceptScore W2591866999C71924100 @default.
• W2591866999 hasIssue "20" @default.
• W2591866999 hasLocation W25918669991 @default.

• next